Comparative Benchmarking
In the context of the broader market, TOVX competes directly with industry leaders such as RDHL and SLXN. With a market capitalization of $6.91M, it holds a leading position in the sector. When comparing efficiency, TOVX's gross margin of N/A stands against RDHL's 60.60% and SLXN's N/A. Such benchmarking helps identify whether Theriva Biologics Inc is trading at a premium or discount relative to its financial performance.
